The global alopecia market size was valued at USD 2.6 billion in 2019 and is expected to expand at a CAGR of 9.5% over the forecast period. Rising prevalence of androgenetic alopecia and alopecia areata diseases is the key factor driving the market growth.
Lifestyle alterations, such as immoderate intake of tobacco and alcohol, and escalating stress indices are considered as strong triggers for the disease. Though the exact disease cause remains unknown, the genetic factors have been linked to several cases. Moreover, rise in disposable incomes as well as building emphasis on aesthetics are poised to drive the market demand and product penetration for alopecia.
Ageing and hormonal anomalies have been listed as potent causative agents for alopecia. Furthermore, gender plays a key role in the disease susceptibility. According to the American Hair Loss Association, it was stated that over 95% of loss of hair in men is caused due to androgenetic alopecia. In addition, steady increase in consumer awareness toward alopecia therapeutic options are likely to positively impact the market in future.
Moreover, rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.
Continuous development of new therapeutic strategies is anticipated to boost growth through the projection period. Emergence of rapid-action JAK inhibitors and hair growth stimulation through PRP treatment and pluripotent stem cells are propelling the market growth. The upcoming launch of some breakthrough products indicate a favorable future for the global market.
Based on disease types, the market is categorized into androgenetic, areata, cicatricial, totalis, universalis, traction, and others. Between the types, alopecia areata dominated the segment in 2019, capturing almost 30% of total market share. The segment growth is supported by a high disease prevalence worldwide and increasing consumer awareness. The disorder is most prevalent in people suffering from autoimmune diseases, namely Down’s syndrome, diabetes, and hyperthyroidism. Alopecia areata can progress into alopecia universalis and totalis.
Androgenetic alopecia is estimated to exhibit the fastest growth, driven majorly by the anticipated launch of multiple promising pipeline candidates and an escalating incidence rate. Androgens spawn the condition in people with genetic disposition to alopecia. Various treatment strategies such as licensed oral, topical, and surgical therapies are accessible for androgenetic alopecia.
Dermatology clinics generated the maximum revenue among all the end-use segments in 2019 and is forecasted to exhibit a lucrative growth rate over next few years. Increasing number of transplantation and restoration surgeries, coupled with widespread application of prescription medicines, are expected to contribute significantly to the market position of dermatology clinics.
Homecare settings are powered by broadening penetration of laser treatment and rise in regulatory sanctions of home-use products. Furthermore, advanced technology, increasing emphasis on convenience, patient compliance, and market presence of contemporary products such as helmets, laser combs, and laser caps are projected to fuel the homecare segment growth.
Key FDA-sanctioned home-use products include Theradome hair grow helmet by Theradome, Inc., iRestore laser hair growth system by Freedom Laser Therapy, Inc., and Hair Max Advanced Laser Comb & HairMax Laser Band 82 by Lexington International.
Based on sales channel, the market is bifurcated into prescription and OTC products. In 2019, prescription products dominated the segment, and is expected to expand at a significant CAGR over the forecast period. Finasteride and corticosteroids are few majorly prescribed products for alopecia.
Increasing demand for cost-effective treatment, easy accessibility of therapies, and addressing adverse effects associated with approved medications are fueling the requirement for OTC medicines. In addition, an upsurge in the quantity of FDA-licensed OTC products for alopecia is another growth-booster.
Alopecia is less prominent in women than in men. According to the U.S. National Library of Medicine and the American Hair Loss Association, nearly 50% men experience some grade of hair fall by 50 years of age. Androgen is a leading cause of androgenetic alopecia in men. Moreover, expanding geriatric population base and increasing intake of tobacco are some of the additional factors poised to augment the alopecia market growth.
Female hair-loss occurs irrespective of age; however, almost 40% of women tend to suffer from hair loss by 50 years of age. Female alopecia is driven by an alarming rise in PCOS incidence rates, escalating number of cosmetic practices, and harmful lifestyle patterns. Increase in health consciousness among women is expected to boost the market growth.
Key regional markets include North America, Asia Pacific, Europe, Latin America, and Middle East and Africa (MEA). North America contributed more than 34.0% market share in 2019. Enlarging disease prevalence, technological advancements, novel product development, and increasing disposable income are few contributors of North America’s market share.
Asia Pacific region is positioned to exhibit the fastest growth over the next few years. Large population base and rising consumer awareness toward available treatment options are the key factors driving the regional growth. Economic betterment and increased per capita healthcare spending, in developing countries such as India, China, and Singapore are expected to create strong commercial opportunities.
Some of the major companies operating in the market include Johnson and Johnson Services, Inc.; Sun Pharmaceutical Industries Ltd.; Cipla Inc.; Lexington International LLC; Merck & Co., Inc.; Vita-Cos-Med Klett-Loch GmbH; Cirrus Hair Centers; Transitions Hair Pty Ltd.; Capillus; and Follica, Inc.
Rising R&D activities to improve treatment options, accelerated regulatory approvals, and strategic business initiatives undertaken by the key players sum up the major competitive approaches paving the road for expansion. For instance, Johnson & Johnson Services, Inc. launched a public health initiative at the global level to provide comprehensive health solutions in Africa, in April 2016.
Base year for estimation
Actual estimates/ Historical data
2015 - 2018
2020 - 2027
Revenue in USD Million and CAGR from 2019 to 2027
North America, Europe, Asia Pacific, Latin America, MEA
Revenue forecast, company share, competitive landscape, growth factors and trends
U.S., Canada, U.K., Germany, Spain, France, Italy, Sweden, Netherlands, Japan, China, India, South Korea, Australia, Taiwan, Vietnam, Thailand, Malaysia, Singapore, Indonesia, Philippines, Brazil, Mexico, Argentina, South Africa, Turkey, Egypt, Iran, Israel, Saudi Arabia, UAE
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2027. For the purpose of this study, Grand View Research has segmented the global alopecia market report on the basis of disease type, end use, sales channel, gender, and region:
Disease Type Outlook (Revenue, USD Million, 2015 - 2027)
End-use Outlook (Revenue, USD Million, 2015 - 2027)
Sales Channel Outlook (Revenue, USD Million, 2015 - 2027)
Gender Outlook (Revenue, USD Million, 2015 - 2027)
Regional Outlook (Revenue, USD Million, 2015 - 2027)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.